EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS
Publication
, Conference
Thompson, E; Landi, D; Ashley, D; Keir, S; Bigner, D
Published in: Neuro-Oncology
November 5, 2018
Duke Scholars
Published In
Neuro-Oncology
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl_6
Start / End Page
vi102 / vi102
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, E., Landi, D., Ashley, D., Keir, S., & Bigner, D. (2018). EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. In Neuro-Oncology (Vol. 20, pp. vi102–vi102). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noy148.426
Thompson, Eric, Daniel Landi, David Ashley, Steve Keir, and Darell Bigner. “EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” In Neuro-Oncology, 20:vi102–vi102. Oxford University Press (OUP), 2018. https://doi.org/10.1093/neuonc/noy148.426.
Thompson E, Landi D, Ashley D, Keir S, Bigner D. EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. In: Neuro-Oncology. Oxford University Press (OUP); 2018. p. vi102–vi102.
Thompson, Eric, et al. “EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS.” Neuro-Oncology, vol. 20, no. suppl_6, Oxford University Press (OUP), 2018, pp. vi102–vi102. Crossref, doi:10.1093/neuonc/noy148.426.
Thompson E, Landi D, Ashley D, Keir S, Bigner D. EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS. Neuro-Oncology. Oxford University Press (OUP); 2018. p. vi102–vi102.
Published In
Neuro-Oncology
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 5, 2018
Volume
20
Issue
suppl_6
Start / End Page
vi102 / vi102
Publisher
Oxford University Press (OUP)
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences